Cardiac troponin and β-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis
Cardiac troponin and β-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis
复制标题
DOI：
10.1016/s0009-8981(01)00392-8
复制
发表时间：
2001-04-01
影响因子：
5
通讯作者：
Mair, J
中科院分区：
文献类型：
--
作者：
Erlacher, P;Lercher, A;Mair, J
研究人员测量了 39 名没有心脏受累临床证据的多发性肌炎 (PM) 或皮肌炎 (DM) 患者的血液样本中的心肌肌钙蛋白 T (cTnT)、心肌肌钙蛋白 I (cTnI)、肌球蛋白重链 (MHC)、肌红蛋白、肌酸激酶 (CK) 和肌酸激酶同工酶 MB (CKMB)，以评估其在该患者群体中的临床有效性。 MHC、肌红蛋白和 CKMB 经常升高，并且彼此相关且与疾病严重程度相关。除一名患者外，所有患者均检测不到 cTnI，表明 MHC 从骨骼肌中释放，从而提供了 PM 或 DM 患者频繁出现慢肌纤维坏死的第一个实验室证据。 51% 的患者 CKMB 升高，41% 的患者升高 cTnT，只有 2.5% 的患者升高 cTnI，cTnI 与其他标志物或疾病严重程度评分不相关。 cTnT 与骨骼肌损伤标志物之间的密切相关性以及 cTnT 与疾病严重程度之间的关系（没有心肌损伤的临床证据）表明 cTnT 从骨骼肌中释放。 cTnT 与疾病严重程度的关系表明该标记物可能在风险分层中发挥作用。然而，心肌肌钙蛋白和其他肌肉损伤标志物对 PM/DM 患者的预后价值仍有待在前瞻性结果试验中进行比较。 (C) 2001 Elsevier Science B.V. 保留所有权利。
Cardiac troponin T (cTnT), cardiac troponin I(cTnI), myosin heavy chains (MHC), myoglobin, creatine kinase (CK), and creatine kinase isoenzyme MB (CKMB), were measured in blood samples from 39 polymyositis (PM) or dermatomyositis (DM) patients without clinical evidence for cardiac involvement to evaluate their clinical usefulness in this patient population. MHC, myoglobin, and CKMB were frequently elevated and correlated with each other and with disease severity. Undetectable cTnI in all but one patient indicated that MHC was released from skeletal muscle, thereby providing the first laboratory evidence of frequent slow-twitch muscle fibre-necrosis in patients with PM or DM. CKMB was elevated in 51%, cTnT in 41%, and cTnI in only 2.5% of patients, cTnI did not correlate with other markers or with disease severity scores. The close correlations found between cTnT and skeletal muscle damage markers and the relationship between cTnT with disease severity without clinical evidence for myocardial damage suggest a release of cTnT from skeletal muscle. The relationship of cTnT with disease severity indicates a possible role of the marker for risk stratification. However, the prognostic values of cardiac troponins and other muscle damage markers in PM/DM patients remain to be compared in prospective outcome trials. (C) 2001 Elsevier Science B.V. All rights reserved.